These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12911603)

  • 1. Asymptomatic excessive coumarin anticoagulation is a risk factor for thrombotic and bleeding complications of oral anticoagulant therapy.
    Poli D; Antonucci E; Gensini GF; Abbate R; Prisco D
    J Thromb Haemost; 2003 Aug; 1(8):1840-1. PubMed ID: 12911603
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications.
    ten Berg JM; Hutten BA; Kelder JC; Verheugt FW; Plokker HW
    Circulation; 2001 Apr; 103(16):2042-7. PubMed ID: 11319192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content.
    Booth SL; Charnley JM; Sadowski JA; Saltzman E; Bovill EG; Cushman M
    Thromb Haemost; 1997 Mar; 77(3):504-9. PubMed ID: 9066002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of coumarin-associated coagulopathy in the non-bleeding patient: a systematic review.
    Dentali F; Ageno W
    Haematologica; 2004 Jul; 89(7):857-62. PubMed ID: 15257939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.
    Choppin A; Irwin I; Lach L; McDonald MG; Rettie AE; Shao L; Becker C; Palme MP; Paliard X; Bowersox S; Dennis DM; Druzgala P
    Br J Pharmacol; 2009 Nov; 158(6):1536-47. PubMed ID: 19845677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
    Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
    Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitamin K and coumarin anticoagulants: dependence of anticoagulant effect on inhibition of vitamin K transport.
    Lowenthal J; Birnbaum H
    Science; 1969 Apr; 164(3876):181-3. PubMed ID: 5774189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Adverse reactions of coumarin derivative interactions].
    Wiela-Hojeńska A; Orzechowska-Juzwenko K
    Pol Merkur Lekarski; 2000 Sep; 9(51):600-1. PubMed ID: 11126983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of 3-amino-4-hydroxy coumarin and dihydroxy-phenyl coumarins as novel anticoagulants.
    Danis O; Yuce-Dursun B; Gunduz C; Ogan A; Sener G; Bulut M; Yarat A
    Arzneimittelforschung; 2010; 60(10):617-20. PubMed ID: 21125812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin-induced changes in procoagulant and anticoagulant proteins.
    Stirling Y
    Blood Coagul Fibrinolysis; 1995 Jul; 6(5):361-73. PubMed ID: 8589201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin Necrosis Induced by Coumarin Congeners.
    Fred HL
    Tex Heart Inst J; 2017 Aug; 44(4):233-236. PubMed ID: 28878574
    [No Abstract]   [Full Text] [Related]  

  • 12. [Anticoagulant action of a new synthetic derivative of 4-hydroxycoumarin and antagonism by synthetic vitamin K1 in the rat].
    Thonnart N; Letist D; Reuse JJ
    C R Seances Soc Biol Fil; 1973; 167(6):1081-5. PubMed ID: 4803162
    [No Abstract]   [Full Text] [Related]  

  • 13. [Oral anticoagulation with vitamin K antagonists].
    Alberio L
    Ther Umsch; 2003 Jan; 60(1):5-9. PubMed ID: 12638470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of coumarins. Significance of vitamin K epoxide.
    Sadowski JA; Suttie JW
    Biochemistry; 1974 Aug; 13(18):3696-9. PubMed ID: 4853124
    [No Abstract]   [Full Text] [Related]  

  • 15. [Bleeding risk and perioperative management of patients anticoagulated with vitamin K antagnosists].
    Angelo M; Stockner I; Wiedermann CJ
    Wien Med Wochenschr; 2008; 158(21-22):615-20. PubMed ID: 19052707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Images in vascular medicine. Coumarin skin necrosis: a severe complication of oral anticoagulation.
    Brodmann M; Seinost G; Pilger E
    Vasc Med; 2006 Nov; 11(4):273. PubMed ID: 17390556
    [No Abstract]   [Full Text] [Related]  

  • 17. Patient self-monitoring of oral anticoagulant therapy: potential benefits and implications for clinical practice.
    Douketis JD
    Am J Cardiovasc Drugs; 2001; 1(4):245-51. PubMed ID: 14728024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation.
    Watzke HH; Forberg E; Svolba G; Jimenez-Boj E; Krinninger B
    Thromb Haemost; 2000 May; 83(5):661-5. PubMed ID: 10823258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extensive coumarin-induced necrosis - a vasculopathy following oral anticoagulation.
    Magnolo N; Jeskowiak A; Goerge T
    J Dtsch Dermatol Ges; 2014 Mar; 12(3):263-4. PubMed ID: 24533794
    [No Abstract]   [Full Text] [Related]  

  • 20. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.